Fixed-dose combination antituberculosis therapy as a risk factor for tuberculosis recurrence: an evidence-based case report
Background: a patient with a history of tuberculosis (TB) has a risk up to 27% to develop recurrence within 2 years after being cured. Indonesia itself has more than 7,500 recurrent cases annually, regardless of reinfection or relapse. This is an important problem, as recurrent TB is associated with...
Auteurs principaux: | Arvin Pramudita, Cleopas M Rumende, Ardi Findyartini |
---|---|
Format: | Article |
Langue: | English |
Publié: |
Interna Publishing
2017-04-01
|
Collection: | Acta Medica Indonesiana |
Sujets: | |
Accès en ligne: | http://www.actamedindones.org/index.php/ijim/article/view/327 |
Documents similaires
-
Treating more with less: Effectiveness and event outcomes of antituberculosis fixed-dose combination drug versus separate-drug formulation (Ethambutol, Isoniazid, Rifampicin and Pyrazinamide) for pulmonary tuberculosis patients in real-world clinical practice
par: Jacqueline Mui Lan Lai, et autres
Publié: (2019-01-01) -
Relative Bioavailability of Rifampicin in Four Chinese Fixed-dose Combinations Compared with Rifampicin in Free Combinations
par: Hui Zhu, et autres
Publié: (2015-01-01) -
Comparison of the safety and efficacy of a fixed-dose combination regimen and separate formulations for pulmonary tuberculosis treatment
par: Jiun-Ting Wu, et autres
Publié: (2015-06-01) -
In vitro antimicrobial efficacy of a fixed-dose combination of RHZE against M. tuberculosis
par: Vanessa Albertina Agertt, et autres -
Potential side effects of medicine on patients with tuberculosis fixed-dose combination in dr. Pirngadi Hospital, Medan
par: EVA SARTIKA DASOPANG, et autres
Publié: (2020-02-01)